DPP-4 traffic jam

DPP-4 traffic jam

By Michael Flanagan Senior Writer

Unlike the next wave of GLP-1 mimetics, which are expected to offer successively less frequent dosing and easier compliance for Type II diabetics, data on the new contingent of DPP-4 inhibitors at last week's American Diabetes Association meeting didn't show any obvious advantages over Januvia sitagliptin from Merck & Co. Inc.

Given the apparent similarities in potency, dosing and side effect profiles, the question remains whether doctors will use a newer DPP-4 instead of one with a proven track record. The first company to test the waters could be Takeda Pharmaceutical Co. Ltd., which submitted an NDA late last year for

Read the full 1065 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE